pms-SUMATRIPTAN is contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias). In addition, patients with other significant underlying cardiovascular diseases (e.g., atherosclerotic disease, congenital heart disease) should not receive pms-SUMATRIPTAN. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal's variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks (TIAs). Peripheral vascular disease includes, but is not limited to, ischemic bowel disease, or Raynaud's syndrome (see Cardiovascular under Precautions).
Because pms-SUMATRIPTAN may increase blood pressure, it is contraindicated in patients with uncontrolled or severe hypertension.
Concurrent administration of MAO inhibitors or use within 2 weeks of discontinuation of MAO inhibitor therapy is contraindicated (see Pharmacology: Pharmacokinetics: Absorption/Metabolism under Actions; Drug-Drug Interactions: MAO Inhibitors under Interactions).
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because pms-SUMATRIPTAN may also cause coronary vasospasm and these effects may be additive, the use of pms-SUMATRIPTAN within 24 hours before or after treatment with other 5-HT1 receptor agonists, or ergotamine-containing drugs or their derivatives (e.g. dihydroergotamine, methysergide) is contraindicated.
pms-SUMATRIPTAN should not be administered to patients with severe hepatic impairment. (See Special Populations: Adults with Severe Hepatic Impairment under Dosage & Administration; Hepatic Impairment under Precautions.)
pms-SUMATRIPTAN is contraindicated in patients with hemiplegic, basilar, or ophthalmoplegic migraine.
pms-SUMATRIPTAN is contraindicated in patients with hypersensitivity to sumatriptan or to any of the ingredients of the formulation, or component of the container. For a complete listing, see Description.